Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study (scientific article)

Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group

Q33396931

Romiplostim in children with chronic immune thrombocytopenia (ITP): the French experience

Q33411082

Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children

Q33415498

Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP).

Q33418391

Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial

Q33424864

Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study

Q33428571

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Romiplostim on Health-Related Quality of Life in Children with Primary Immune Thrombocytopenia and Associated Burden in Their Parents

Q33431165

Intracranial haemorrhage in idiopathic thrombocytopenic purpura. Paediatric Haematology Forum of the British Society for Haematology

Q33491305

Major hemorrhage in children with idiopathic thrombocytopenic purpura: immediate response to therapy and long-term outcome

Q33503661

AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

Q44704490

Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand

Q81126703

Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review

Q26826853

International consensus report on the investigation and management of primary immune thrombocytopenia

Q28262094

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

Q28305486

Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS).

Q30611138

Childhood ITP: 12 months follow-up data from the prospective registry I of the Intercontinental Childhood ITP Study Group (ICIS).

Q30998732

Grading of hemorrhage in children with idiopathic thrombocytopenic purpura

Q33345034

Intracranial hemorrhage in immune thrombocytopenic purpura: a retrospective analysis

Q33349359

Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura

Q33369574

Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids' ITP Tools.

Q33374970

Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura

Q33380732

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

Q33381983

Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response

Q33382172

Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases

Q33386303

Romiplostim in children with chronic refractory ITP: randomized placebo controlled study

Q33394122

P433

issue

10039

P407

language of work or name

English

Q1860

P921

main subject

placebo

romiplostim

thrombocytopenia

page(s)

45-54

P577

publication date

2016-04-18

P1433

published in

The Lancet

Q939416

P1476

title

Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study

P478

volume

388

Reverse relations

cites work (P2860)

Q33435295	A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias
Q33442065	A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia
Q91639087	American Society of Hematology 2019 guidelines for immune thrombocytopenia
Q30399669	Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.
Q33439931	Bleeding tendency and platelet function during treatment with romiplostim in children with severe immune thrombocytopenic purpura
Q59125749	Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
Q33442148	Developmental differences between newborn and adult mice in response to romiplostim
Q50224066	Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenia: a meta-analysis
Q33437732	Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis
Q49534414	Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis
Q90029498	Evidence-based management of immune thrombocytopenia: ASH guideline update
Q92205699	Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia
Q49624514	Management of immune thrombocytopenia: Korean experts recommendation in 2017.
Q47340213	Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Q89777573	Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Q47229048	Peptibodies: An elegant solution for a long-standing problem.
Q52320502	Physician Decision Making in Selection of Second-Line Treatments in Immune Thrombocytopenia in Children.
Q59808505	Platelet count on preoperative day 1 predicts the long-term responses to laparoscopic splenectomy for Chinese patients with medically refractory idiopathic thrombocytopenic purpura
Q88440609	Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy
Q93022562	Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice
Q33438904	Romiplostim for therapy-related thrombocytopenia in pediatric malignancies
Q33437336	Second-line therapies in immune thrombocytopenia
Q47754303	Splenectomy for Immune Thrombocytopenia: Down but not out.
Q33440990	Spotlight on romiplostim in the treatment of children with chronic immune thrombocytopenia: design, development, and potential place in therapy
Q33440145	State of the art - how I manage immune thrombocytopenia
Q64075891	Successful Use of Eltrombopag in a Pediatric Patient With Human Immunodeficiency Virus (HIV)-Associated Thrombocytopenia
Q99630718	Temporal Trends of Intracranial Hemorrhage Among Immune Thrombocytopenia Hospitalizations in the United States
Q41487980	The Centenary of Immune Thrombocytopenia-Part 2: Revising Diagnostic and Therapeutic Approach
Q93156874	The effect of recombinant human thrombopoietin (rhTPO) on sepsis patients with acute severe thrombocytopenia: a study protocol for a multicentre randomised controlled trial (RESCUE trial)
Q96304947	The role of romiplostim for pediatric patients with immune thrombocytopenia
Q91898972	Thrombopoietin receptor agonists: ten years later
Q47898156	Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Q33431692	Treatment of chronic immune thrombocytopenia in children with romiplostim
Q33442354	Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

P356	DOI	10.1016/S0140-6736(16)00279-8
P698	PubMed publication ID	27103127